Morphogenesis of the inner ear epithelium requires coordinated deployment of several signaling pathways and disruptions cause abnormalities of hearing and/or balance. The FGFR2b ligands, FGF3 and FGF10, are expressed throughout otic development and are required individually for normal morphogenesis, but their prior and redundant roles in otic placode induction complicates investigation of subsequent combinatorial functions in morphogenesis. To interrogate these roles and identify new effectors of FGF3 and FGF10 signaling at the earliest stages of otic morphogenesis, we used conditional gene ablation after otic placode induction and temporal inhibition of signaling with a secreted, dominant-negative FGFR2b ectodomain. We show that both ligands are required continuously after otocyst formation for maintenance of the otic ganglion and patterning and proliferation of the epithelium, leading to normal morphogenesis of both the cochlear and vestibular domains. Furthermore, the first genomewide identification of proximal targets of FGFR2b signaling in the early otocyst reveals novel candidate genes for inner ear development and function.
ABSTRACT
Morphogenesis of the inner ear epithelium requires coordinated deployment of several signaling pathways and disruptions cause abnormalities of hearing and/or balance. The FGFR2b ligands, FGF3 and FGF10, are expressed throughout otic development and are required individually for normal morphogenesis, but their prior and redundant roles in otic placode induction complicates investigation of subsequent combinatorial functions in morphogenesis. To interrogate these roles and identify new effectors of FGF3 and FGF10 signaling at the earliest stages of otic morphogenesis, we used conditional gene ablation after otic placode induction and temporal inhibition of signaling with a secreted, dominant-negative FGFR2b ectodomain. We show that both ligands are required continuously after otocyst formation for maintenance of the otic ganglion and patterning and proliferation of the epithelium, leading to normal morphogenesis of both the cochlear and vestibular domains. Furthermore, the first genomewide identification of proximal targets of FGFR2b signaling in the early otocyst reveals novel candidate genes for inner ear development and function.
INTRODUCTION 1
The membranous labyrinth of the mammalian inner ear is among the most complex examples of 2 organ morphogenesis. An unremarkable patch of cranial ectoderm is transformed into a structurally 3 intricate sensory apparatus with two functionally distinct compartments: the ventral cochlea and the 4 dorsal vestibular system, responsible for the perception of sound and acceleration, respectively. 5
Within these compartments an exquisitely patterned array of sensory, non-sensory and supporting 6 cell types are poised to transduce auditory and vestibular stimuli through sensory ganglia to the 7 brain. Proper morphogenesis of the labyrinth is essential for normal auditory and vestibular function 8 as indicated by imaging studies of hearing loss patients (Kimura et al., 2018; Sennaroglu and Bajin, 9 2017) . In light of the advent of cochlear implantation to treat hearing loss in cases of inner ear 10 malformation (Isaiah et al., 2017) , elucidating signals governing otic morphogenesis and 11 appreciation of the spectrum of labyrinthine morphogenetic defects are necessary to advance 12
treatment. 13
Amniote inner ear development initiates during neurulation when hindbrain proximal ectoderm 14 is induced to thicken, forming the otic placode, the source of both the otic epithelium and the 15 neurons of its sensory ganglia. Next, the placode invaginates, forming a cup that deepens and 16 delaminates neuroblasts, before pinching off from the overlying ectoderm to form a spherical 17 vesicle, the otocyst, that at embryonic day (E)9.5 in mouse is already patterned along the three 18 anatomical axes. Otocyst morphogenesis initiates with dorsomedial budding to form the 19 endolymphatic duct and sac (EDS) anlagen. Vestibular structures initiate by sequential dorsal and 20 lateral evaginations of the epithelium to form vertical and horizontal pouches, which are further 21 sculpted by epithelial fusion and resorption, generating the three orthogonal semicircular canals. The 22 utricle and saccule form from anterior/central bulges, and the cochlear duct (CD) emerges as a 23 ventral outgrowth. In mice, it undergoes progressive ventral extension and coiling, reaching 1.75 24 turns by E15.5, when gross morphogenesis is largely complete (Morsli et al., 1998; Sajan et al., 25 2007) . Cell type differentiation and functional maturation however, continue until well after birth 26 (reviewed in Alsina and Whitfield, 2017; Basch et al., 2016; Whitfield, 2015; Wu and Kelley, 2012) . 27
Signals regulating otic placode induction and early otocyst patterning emanate from surrounding 28 tissues and are understood in some detail (Ladher, 2017) , but by otocyst stages, intrinsic signals are 29 also produced and their roles in driving region-specific morphogenesis are less well understood. 30
Extrinsic signals regulating dorsal morphogenesis include hindbrain WNTs and BMPs. SHH 31 secreted from the ventral hindbrain and notochord initiates ventral morphogenesis. Crosstalk 32 between these signals involves regulation of key region-specific transcription factors (Ohta and 33 Schoenwolf, 2018) . FGF signaling also plays critical roles in otic development and functions at 1 multiple stages. A cascade of FGFs from endoderm, mesoderm and hindbrain is required for otic 2 placode induction (Alvarez et al., 2003; Ladher et al., 2005; Wright and Mansour, 2003a; Zelarayan 3 et al., 2007) . In particular, Fgf3 and Fgf10, encoding ligands that signal through the same FGF 4 receptor isoforms (FGFR1b and FGFR2b; Zhang et al., 2006) , are required redundantly for otic 5 placode induction, such that germline double null mutants (F3KO;F10KO) have no inner ear 6 (Alvarez et al., 2003; Wright and Mansour, 2003a) . Applications of FGFs and FGFR inhibitors to 7 chick embryos revealed profound influences of FGFs on otic morphogenesis (Chang et al., 2004) 8 and studies of individual mouse mutants revealed roles for Fgf3 and Fgf10 in morphogenesis. Mice 9 lacking Fgf3 (F3KO) fail with variable penetrance and expressivity to form an EDS, and 10 consequently have variable morphogenesis and dysfunction of both the cochlea and vestibule (Hatch 11 et al., 2007; Mansour et al., 1993) . Mice lacking Fgf10 (F10KO) fail to form posterior semicircular 12 canals (PSCCs), and have milder deformations of the anterior and lateral canals. Fgf10 13 heterozygotes also exhibit PSCC reductions or agenesis (Pauley et al., 2003; Urness et al., 2015) . 14 The CD is also affected in Fgf10 null mutants, being shorter and narrower than that of heterozygous 15 or wild-type mice due to loss of non-contiguous non-sensory domains (Urness et al., 2015) . Fgfr2b 16 null mutants form otocysts (Pirvola et al., 2000) , however, they develop with severe cochlear and 17 vestibular dysmorphology, suggesting that Fgf3 and Fgf10 could have additional and combinatorial 18 roles during morphogenesis. 19
Here, we define the dynamic expression of Fgf3 and Fgf10 in the developing mouse otic 20 epithelium and ganglion, and interrogate their functions after otic placode induction. We employ two 21 complementary genetic strategies: otic placode lineage-restricted gene ablation and timed induction 22 of a soluble dominant-negative FGFR2b ectodomain that acts rapidly as an extracellular ligand trap 23 to block signaling. Together, our data show that Fgf3 and Fgf10 are not required in the placode 24 lineage for otocyst formation, but are required subsequently for otocyst patterning, neuroblast 25 maintenance, epithelial proliferation and both vestibular and cochlear morphogenesis. Furthermore, 26 the first differential RNA-Seq analyses of otocysts revealed FGFR2b signaling targets that define 27 novel candidates for genes involved in otic morphogenesis and function. 28
29

RESULTS 30
Fgf3 and Fgf10 are expressed dynamically during otocyst and ganglion formation, and 31
cochlear morphogenesis 32
To determine Fgf3 and Fgf10 expression during otocyst formation and cochlear morphogenesis, we 1 used RNA in situ hybridization (ISH). Before E9.0, both genes were exclusively periotic (data not 2 shown). Consistent with previous studies (Schimmang, 2007; Wright and Mansour, 2003b) , Fgf3  3 and Fgf10 transcripts were non-overlapping at the otic cup stage, with Fgf3 expressed in hindbrain 4 adjacent to the cup (Fig. 1A) , and Fgf10 expressed in the cup itself, exclusive of the dorsal and 5 lateral-most regions (Fig. 1B) . Once the otocyst closed, Fgf3 was diminished in the hindbrain and 6 was first seen in the ventrolateral otocyst and in the forming otic ganglion (Fig. 1C ), whereas Fgf10 7 was expressed in the ventral and medial otocyst ( Fig. 1D ). By E10.25-E11.25, Fgf3 was confined to 8 the ventrolateral otocyst (Figs. 1E, G) . At this stage, Fgf10 overlapped with and was more 9 extensively expressed in the ventral otocyst than was Fgf3, and also began to be expressed strongly 10 in the ganglion (Figs. 1F, H) . 11
We confirmed overlap of Fgf3 and Fgf10 in the developing vestibular sensory tissues, with 12
Fgf10 expression much stronger than Fgf3 (data not shown; see Pauley et al., 2003; Pirvola et al., 13 2000) . Therefore, we focused on the developing CD. From E12.5-E16.5, we found Fgf3 in a 14 progressively limited portion of the CD that appeared by E16.5 to flank the developing sensory 15 organ of Corti (Figs. 1I,K,M,O). Fgf10 continued expression in a broader cochlear epithelial domain 16 than Fgf3, resolving to Kölliker's organ by E16.5, and was maintained at high levels in the cochlear 17 ganglion (Figs. 1J,L,N,P). These observations suggested that after otic induction, Fgf3 and Fgf10 18 could have combinatorial roles in morphogenesis and ganglion development. 19 20 Epithelial Fgf3 and Fgf10 are not required for otocyst formation, but both are required for 21
vestibular and cochlear morphogenesis 22
Since F3KO;F10KO embryos lack inner ears (Alvarez et al., 2003; Wright and Mansour, 2003a) , we 23 took a conditional approach to disrupt these genes individually and combinatorially after otic 24 placode induction using Tg(Pax2-Cre), which is active in the otic placode lineage starting at E8.5 25 ( Fig. 2A ; Ohyama and Groves, 2004) . As this lineage comprises both epithelium and ganglion, 26
Tg(Pax2-Cre) recombines in both tissues (Figs. 2B, C) . In contrast to the variable otic phenotypes 27 observed in F3KO mutants (Hatch et al., 2007; Mansour et al., 1993) , deletion of Fgf3 alone in the 28 Pax2-Cre lineage (F3cKO) had no effect on otic morphogenesis at E15.5 (Figs. 2D, D') At E10.5, expression of several other genes was still unaffected, as exemplified by Gbx2 ( Fig.  26 3E 1 -E 5 ), which is expressed dorsomedially, is down-regulated at this stage in F3KO mutants (Hatch 27 et al., 2007) , and is required for vestibular morphogenesis (Lin et al., 2005) . Other genes unaffected 28 by loss of Fgf3 and Fgf10 at E10.5 included Hmx3, Spry2, Gli1, Id1, and Lfng (data not shown). In 29 contrast, Sox2, Foxg1 and Bmp4, which are primarily lateral at E10.5, were all unaffected, except in 30
F3cKO;F10cKO ears, where expression was extinguished (Figs. 3F 5 ,G 5 ,H 5 ). Other genes lost from 31 E10.5 F3cKO/F10cKO otocysts included Dusp6, Etv5, Etv4, and Spry2 (data not shown), all of 32 which are known transcriptional targets of FGF signaling. Curiously, we found that Pax2, which at 33 E10.5 is normally expressed medially ( Fig. 3I 1 ) , was unchanged in all otocysts except 1 F3cKO/F10cKO, where it was expanded (Figs. 3I 1 -I 5 ). 2 By E11.5 the only tested genes still unaffected in F3cKO;F10cKO otocysts were Gli1, Hmx3, 3
Lfng and Id1 (data not shown), so these are unlikely to be targets of FGF3/FGF10 signaling in the 4 otocyst. Whether the affected genes are direct or indirect targets of FGF signaling at this stage could 5 not be determined. 6
To assess the otic ganglion, we assayed Neurog1 and its target, Neurod1, at both E9.5 and E10.5. 7
At E9.5, all genotypes exhibited similar expression in a ventrolateral epithelial domain and in 8 delaminating neuroblasts (Figs. 3J 1 -J 5 ,3L 1 -L 5 ). In contrast, at E10.5 Neurog1 was strongly reduced 9
and Neurod1 was virtually eliminated from the otic epithelium, and otic ganglion development was 10 suppressed specifically in F3cKO/F10cKO otocysts (Figs. 3K 5 , M 5 ). These data show that 11 epithelial/ganglion expression of Fgf3 and Fgf10 are required for aspects of gene expression driving 12 otic morphogenesis, particularly in lateral regions, and that they are also required for otic ganglion 13 formation. 14 15 Doxycycline induction of a secreted FGFR2b ectodomain phenocopies Fgf3/Fgf10 double null 16 mutants 17 FGF3 and FGF10 bind to and signal primarily through "b"-type FGF receptors (FGFR2b>FGFR1b, 18 Zhang et al., 2006) . To enable simultaneous and inducible inhibition of their signaling activity at any 19 stage, we employed two alleles that together enable doxycycline (DOX)-inducible expression of a 20 secreted, dominant-negative form of FGFR2b (dnFGFR2b), which serves as a ligand trap. Rosa26 rtTA 21 drives ubiquitous expression of the reverse tetracycline transactivator (Belteki et al., 2005) and 22 Tg(tetO-dnFgfr2b) encodes a tetO-regulated and secreted FGFR2b ectodomain (Hokuto et al., 23 2003) . This system is validated for temporally controlled inhibition of mammary gland, tooth, limb 24 and lung development, which depend on various FGFR2b and FGFR1b ligands (Al Alam et al., 25 2015; Danopoulos et al., 2013; Parsa et al., 2010; Parsa et al., 2008) . 26 To validate this system for inner ear studies we crossed the alleles together, fed DOX-chow to 27 pregnant females from E5.5-E10.5 and observed gross embryonic phenotypes. Relative to 28 Rosa26 rtTA/+ embryos, which appeared normal ( Fig. 4A ), double heterozygotes had a short curly tail, 29 lacked limb buds and had tiny otic vesicles ( Fig. 4B ), phenocopying F3KO;F10KO mutants. Double 30 heterozygotes exposed to DOX from E5.5 or E6.5 to E11.5 showed only an otic remnant (Fig. S2 ) 31 and they did not exhibit mid-hindbrain phenotypes characteristic of inhibition of ligands such as 32 FGF8 and FGF17, that signal through "c"-type FGFRs (Chi et al., 2003; Sato and Joyner, 2009; Xu 1 et al., 2000) . 2 3
Secreted dnFGFR2b acts rapidly to inhibit signaling by FGFR2b ligands 4
To determine the timing of signaling inhibition we initiated dnFGFR2b expression by injecting DOX 5 at different stages, providing DOX-chow for various intervals, and assaying for Etv5 expression by 6 ISH. After only 4 hours of DOX starting at E9.5, Tg(tetO-dnFgfr2b)/+ embryos showed robust Etv5 7 expression in numerous sites of FGF signaling ( Fig. 4C ), including throughout most of the otic 8 vesicle ( Fig. 4C') . In contrast, double heterozygotes retained many sites of Etv5 expression, but 9 lacked any otic Etv5 (Fig. 4D,D' ). In addition, 6 hours of DOX starting at E8.25 caused a near 10 ablation of Etv5 throughout double heterozygotes, including in the otic cup ( Fig. S3A,A' consistent with studies of dnFGFR2b induction in the limb (Danopoulos et al., 2013) . 14
15
FGFR2b ligands are required continuously for otic morphogenesis 16
Next, we asked when FGFR2b ligands are required for otocyst morphogenesis. Starting between 17 E8.5 and E13.5 we injected DOX into pregnant dams and provided DOX-chow continuously 18 through E15.5 when the inner ears were paintfilled. We compared Rosa26 rtTA/+ (control) to 19 Rosa26 rtTA/+ ;Tg(tetO-dnFgfr2b)/+ (experimental) samples. DOX exposure from E8.5-E15.5 20 inhibited inner ear development such that experimental embryos had no otic tissue to fill (n=6/6; 21 data not shown). When DOX was started on E9.5, control ears appeared normal ( Fig. 4E ) and 22 experimental samples showed two distinct phenotypes: either no detectable inner ear (n=6/10; not 23 shown) or a structure resembling an EDS (n=4/10; Fig. 4F ). Starting DOX on E10.5 blocked 24 development of distinct SCCs from the vertical canal pouch, reduced the size of the saccule and 25 utricle, and caused a dramatic shortening and narrowing of the CD (n=16/18; Fig. 4G ). This 26 phenotype resembled the most strongly affected F10KO mutants (Urness et al., 2015) . DOX 27 exposure from E11.5-E15.5 was compatible with SCC formation, though these appeared thinner than 28 those of control ears (n=8/8; Fig. 4H ). Development of the utricle, saccule and CD were somewhat 29 variable, but not markedly better than in the E10.5-E15.5 samples. Inner ears exposed to DOX from 30 E12.5-E15.5 had a much more normal morphology, but still, the SCCs and CD were narrow (n=8/8; 31 Fig. 4I ). Even experimental ears exposed to DOX from only E13.5-E15.5 showed the thin SCC 32 defect, but the rest of the inner ear appeared grossly normal (n=8/8; Fig. 4J ). These data show that 1 To determine more precise intervals for FGFR2b ligand requirements in particular events of otic 6 morphogenesis, we treated pregnant dams with different DOX pulses and examined E15.5 inner ears 7 by paintfilling. As expected, all ears exposed to DOX for even the longest pulse (24 h) had normal outgrowth and formation of at least a vertical canal pouch, but no SCC formation. In addition, the 22 CD was short and narrow (n=14/16) or not present (n=2/16; Fig. 5L ,L'). DOX exposures starting at 23 9 AM on E10.5 (termed E10.25) and extending for 4 or 6 hours consistently blocked normal PSCC 24 formation (n=19/20; both groups considered together) and the 6-hour exposure sometimes affected 25 the ASCC as well (n=3/10), but had virtually no effect on development of the utricle, saccule or CD 26 E10.5 (termed E10.75), the most severe defects were avoided, nevertheless, the SCCs appeared thin, 28 the utricle and saccule were reduced and the CD was short (n=5/5; Fig. 5R ). In summary, we found 29 that the earlier DOX was started and the longer it was present, the more severe were the 30 morphogenesis defects. Furthermore, some of the DOX pulses gave such consistent outcomes that it 31 seemed possible to identify acute epithelial transcriptional targets of FGFR2b ligands mediating 32 particular morphogenetic events. 33 1
RNA-Seq reveals transcriptional targets of FGFR2b ligands during early otic morphogenesis 2
To identify transcriptional targets of FGFR2b ligands during early otocyst morphogenesis, when 3 they are required for both vestibular and cochlear outgrowth, we chose three DOX exposures (Fig. 4 6A) that gave similar morphogenesis outcomes: E9.75+12 hours (Seq1, Figs. 5L,L'), E10.25+24 5 hours (Seq2, Figs. 5P,P') and E9.25+24 hours (Seq3, Figs. 5J,J'). Immediately following DOX 6 exposure, otocysts were microdissected, cleaned of mesenchyme (Fig. 6B ), and pooled into separate 7 control and experimental groups from each female. RNA was isolated, processed for RNA-Seq and 8 analyzed for differential expression under both unpaired (genotype only) and paired (genotype and 9 litter) statistical models. 10
Differentially expressed genes with an adjusted (adj) P<0.05 in each paired dataset were 11 visualized with volcano plots ( Fig. 6C; Fig. S4 ). In all 3 datasets the maximum fold-changes were 12 relatively modest, perhaps reflecting the short periods of inhibition, but for many genes the 13 differences were highly significant. Fgfr2 and Ighg1 were among the most highly differentially 14 expressed Seq1 genes (5.3-fold and 633-fold induced, respectively, but Ighg1 was omitted from the 15 plot for legibility; Fig 6C) . Inspection of Fgfr2 reads showed upregulation was due to expression of 16 the Fgfr2b splice isoform specifically in transgene-containing samples. The Ighg1 reads were also 17 transgene-specific, thus validating the efficacy of the inductions. Excluding Fgfr2 and Ighg1 as 18 vector-specific, there were 968 genes >1.5-fold upregulated and 631 genes >1.5-fold downregulated 19 (adjP<0.05) in experimental otocyst RNA. Significantly downregulated genes included well-known 20 transcriptional targets of FGF signaling including Etv1, Etv4, Etv5, Dusp6, Spry2 and Spry1 21 (indicated in Fig. 6C and listed, Excel S1). Similar analyses of Seq2 and Seq3 also showed 22 significant upregulation of vector-specific sequences and significant downregulation of known FGF 23 target genes ( Fig. S4 , listed in Excel S1). To validate an FGF target gene significantly 24 downregulated in all 3 datasets, we detected Etv5 by ISH of otocyst sections. Seq1 control otocysts 25 showed lateral and ventromedial Etv5 expression, whereas experimental embryos did not express 26 otocyst Etv5 (Fig. 6D ,E). Similar results were obtained with Seq3 samples (Fig. S5) . 27
Fgfr1 sequence reads in each dataset showed no changes in level between control and 28 experimental samples, which were similar to control levels of Fgfr2. Interestingly, Fgfr1c, thought 29 to be mesenchymal, was the predominant splice isoform, but Fgfr1b was also detected. Fgfr3 30 sequences were present at levels at least 20-fold below those of Fgfr1 or Fgfr2 in control samples 31 and were unchanged by dnFGFR2 induction (Excel S1). The only FGFR2b ligand genes expressed 32 at significant levels in control or experimental otocysts were Fgf3 and Fgf10 (Excel S1), consistent 33 with ISH surveys and data not shown). Interestingly, Fgf3 was slightly, but 1 significantly upregulated in all 3 datasets. However, as dnFGFR2b inhibition acts at the level of 2 protein, this is unlikely to impact the phenotypes. 3 4 FGFR2b ligands are required to promote otocyst cell proliferation 5
To explore functional relationships between significantly differentially expressed genes in each 6 dataset (either up or downregulated; adjP<0.05), we used Ingenuity Pathway Analysis. In each case, 7 the top 5 affected pathways included cell cycle and DNA damage/repair pathways (Excel S2; -log(P-8 value)=8-13). In most cases these genes were downregulated in our datasets. In addition, we used 9
GOrilla software to identify gene ontology terms for processes enriched in the downregulated Seq1 10 dataset (adjP<0.05), and the results were similar (top 5 shown in Excel S2; FDR q-values 1.55x10 -11 21 -7.84x10 -13 ). To assess proliferation more directly, we quantified pHH3-positive cells per otic 12 epithelial area in Seq3 otocyst sections and found a significant ~1.8-fold decrease in pHH3 labeling 13 of experimental samples relative to controls ( Fig. 6F-H ), suggesting that one role for FGFR2b 14 ligands during E9.25-E10.25 is to control the rate of otic epithelial proliferation. 15 16
Signaling by FGFR2b ligands in the early otocyst represses genes that function later in otic 17 epithelial development or hearing 18
Among the significantly upregulated genes in dnFgfr2b samples from the Seq1 paired analysis, we 19 noticed a gene that, when mutated, causes human hearing loss (Gjb6; Fig. 6C ). To determine 20 whether other such genes, or those responsible for mouse hearing loss and/or cochlear development, 21
were enriched in either the up-or downregulated genesets, we conducted a gene set enrichment 22 analysis (Subramanian et al., 2005) and 2.06 for the mouse genes; both nominal P-values, <1x10 -3 ), but not in the downregulated set. 28
Similar results were obtained with the Seq2 dataset (data not shown). Together, these analyses 29 suggest that one role of FGFR2b ligands at this early stage of morphogenesis is to prevent premature 30 expression of epithelial genes that have later roles in development or function of the inner ear. 31
Validation of new genes regulated by FGFR2b ligands during the early stages of otocyst 1 morphogenesis 2
To validate new FGFR2b target genes by ISH we focused first on downregulated genes and assayed 3 selected genes based on overlap in multiple RNA-Seq datasets (Excel S5), relatively high degree of 4 differential expression, and normalized read count above that of Fgf3 (Excel S1), which is relatively 5 difficult to detect by ISH, and novelty with respect to inner ear development and/or FGF/MAPK 6 signaling. Seven genes validated as downregulated in Seq1 otocysts are illustrated in Figure 7 . 7
Spred3 was expressed in E10.25 control otocysts in a ventromedial domain (Fig. 7A ), and was 8 greatly reduced in experimental otocysts ( Fig. 7A') . Six2 was detected in the ventral-most region of 9 control otocyts as well as laterally ( Fig. 7B ), but was absent from dnFGFR2b otocysts ( Fig. 7B') . was expressed in the ventral-most region of controls ( Fig. 7F ) and was absent from dnFGFR2b 16 otocysts ( Fig. 7F') . Finally, Gchfr was expressed similarly to Pou3f3 (Fig. 7G ) and was absent from 17 dnFGFR2b otocysts ( Fig. 7G') . We observed similar downregulation of Spred3, Prdm1, Crlf1, 18
Tspan15, and Gchfr expression in dnFGFR2b otocysts subjected to the Seq2 and Seq3 DOX 19 exposures (Figs. S6,S7). Six2 and Pou3f3 downregulation was confirmed by ISH in Seq3 otocysts 20 ( Fig. S7 ), but not tested in Seq2 otocysts, as these genes were not significantly affected in the Seq2 21
dataset. 22
We also tested several genes common to the upregulated lists, but most were widely expressed in 23 controls and any changes in expression levels were not revealed by ISH (data not shown). However, 24
Bmper transcripts were confined to the dorsomedial region of control otocysts (Fig. 7H ), but the 25 expression domain expanded to encompass most of the otic epithelium in experimental otocysts ( Fig.  26 7H'). Similar results obtained with Seq2 and Seq3 otocysts (Figs. S6,S7). Therefore, these datasets 27 are a rich source of novel FGFR2b signaling targets in the otocyst. Fgfr2b and two genes encoding FGFR2b ligands, Fgf3 and Fgf10, are required individually for otic 31 morphogenesis (Hatch et al., 2007; Mansour et al., 1993; Pauley et al., 2003; Pirvola et al., 2000; 32 Urness et al., 2015) . We found that Fgf3 and Fgf10 are expressed continuously during otic 33 morphogenesis, however, their requirement for otic placode induction (Alvarez et al., 2003; Urness 1 et al., 2010; Wright and Mansour, 2003a) obscured potential combinatorial roles during otocyst 2 morphogenesis. Here, we blocked FGF3 and FGF10 signaling after otic placode induction by using 3 conditional gene inactivation and temporally controlled inhibition via a drug-inducible ligand trap. 4
Analysis of conditional mutants revealed that both genes are required in the otic lineage after E8.5 5 for both vestibular and cochlear development, but that the role of Fgf3 is only revealed in the 6 absence of Fgf10, and that these signal-encoding genes control expression of genes that function in 7 otic epithelial morphogenesis. Furthermore, we found that FGF3 and FGF10 signal redundantly to 8 maintain otic neuroblasts. Temporally regulated inhibition showed that FGFR2b signaling acts 9 continuously throughout otic morphogenesis and that pulses of inhibition can be used to identify the 10 timing of particular morphogenetic events. We used brief windows of inhibition at early stages of 11 morphogenesis to conduct the first genomewide identification of proximal targets of FGFR2b 12 signaling in the otocyst, and validated several genes that are novel candidates for involvement in the 13 initial stages of otocyst morphogenesis. early otic morphogenesis as, based on RNA-Seq data, the others are either not expressed (Fgf22) or 20 are detected at negligible levels (Fgf1 and Fgf7). The use of stage-matched tissue throughout 21 morphogenesis helped to define the relative temporal and spatial dynamics of the expression patterns 22 and aided in interpreting functional perturbations. We found that Fgf10 has an earlier and broader 23 distribution than Fgf3 in the otic epithelium,and both transcripts are present in the otic ganglion, but 24
Fgf3 is seen only transiently, whereas once Fgf10 starts expressing, it is present continuously at high 25 levels in the cochlear ganglion. Although Fgf10 is expressed in mesenchyme underlying the 26 preplacodal ectoderm, neither gene appears in periotic mesenchyme during otic cup formation or 27 later (Schimmang, 2007; Urness et al., 2015; Wright and Mansour, 2003b) . ISH data for Fgfr2b and 28
Fgfr1b, which encode the receptors for FGF3 and FGF10, are limited because of the small size of 29 probes that distinguish them from "c" isoforms, but extant data are consistent with the idea that they 30 are also primarily epithelial (Orr-Urtreger et al., 1993; Pirvola et al., 2000; Wright et al., 2003; 31 Wright and Mansour, 2003a ) and, indeed, the "b" isoforms are evident in our otocyst RNA-Seq 32 datasets. Therefore, taken together, the ligand and receptor expression data are consistent with our 33 findings of continuous and combinatorial roles for Fgf3 and Fgf10 in otocyst epithelial 1 morphogenesis and otic ganglion development. They also raise the interesting possibility that 2 signaling involves epithelial and/or ganglion ligands activating epithelial, rather than mesenchymal 3 or ganglionic receptors, except perhaps as neuroblasts begin delamination from the epithelium. This 4 contrasts with epithelial ligands FGF9 and FGF20, which signal initially to "c" type receptors in the 5 mesenchyme, inducing signals that control epithelial proliferation (Huh et al., 2015) . 6 7 Fgf3 and Fgf10 are both required for vestibular and cochlear morphogenesis and for 8 maintenance of otic neuroblasts 9
Conditional mutant analyses showed that both genes are required after otic placode induction, but 10 deletion of Fgf3 alone from the Pax2-Cre lineage was inconsequential. This contrasts with the 11 variably penetrant otic dysmorphology of F3KO mutants, the most severe of which initiate with 12 alterations of dorsal otocyst patterning, loss of the EDS, and subsequent cystic development of the 13 epithelium, ultimately resulting in hearing loss and circling behavior (Hatch et al., 2007; Mansour et 14 al., 1993) . The normal phenotype of F3cKO ears points to a critical role for Fgf3 expression in the 15 hindbrain. Indeed, we found that F10KO embryos in which only hindbrain sources of Fgf3 were 16 deleted (using Sox1 Cre ) had very small otocysts. In contrast, F10cKO ears had abnormalities very 17 similar to those of F10KO ears. This demonstrates that the unique functions of Fgf10 in otic 18 morphogenesis arise from its expression in the placodal lineage rather than earlier in the 19 mesenchyme. Analysis of conditional mutants that separate epithelial from ganglion sites of Fgf10 20 expression will be needed to further dissect the spatial requirements for Fgf10 function. 21
Although Pax2-Cre is active in the placode at E8.5, we found no obvious effects at E9.5 on 22 otocyst morphology in F3cKO;F10cKO embryos, and only two tested genes, Etv5 and Tbx1, were 23 lost or altered in these otocysts. The first major losses in expression of multiple genes required for 24 morphogenesis occurred at E10.5. This shows that both Fgf3 and Fgf10 are required in the placode 25 lineage for normal otocyst morphogenesis and suggests that overlapping expression of Fgf3 and 26
Fgf10 starting at E9.5 may be critical for both cochlear and vestibular outgrowth and morphogenesis. 27
However, the phenotypes of triple allelic conditional mutants point to functional differences between 28
Fgf3 and Fgf10. Both the cochlear and vestibular morphology of F3cKO/F10cHet ears were less 29 severely affected than in F3cHet/F10cKO ears. This may reflect the relatively larger domain and 30 higher level of epithelial Fgf10 than of Fgf3, and may be presaged by the differential effects on Etv5 31 expression in the two types of E9.5 otocysts. The loss of dorsolateral Etv5 when Fgf10 is the only 32 remaining allele, and of ventromedial Etv5 when Fgf3 is the only remaining allele, suggest that Fgf3 33 is particularly important dorsally and Fgf10 ventrally, at least initially. The loss of dorsolateral Tbx1 1 in the two most severely affected genotypes likely reflects effects of FGF3/FGF10 signaling on 2 development of the vertical canal pouch, the derivatives of which (PSCC and ASCC) are strongly 3 affected in these and in Tbx1 mutants (Freyer et al., 2013; Macchiarulo and Morrow, 2017) . Whether 4 this is a direct or indirect effect on Tbx1 expression is not yet clear, but it is interesting to note that 5
Tbx1 is slightly, but significantly downregulated in the Seq2 and Seq3 datasets (Excel S1). 6
The presence of an EDS in both triple allelic conditional mutants and normal Gbx2 expression in 7 these mutants and in F3cKO/F10cKO mutants contrasts with findings from F3KO mutants (Hatch et 8 al., 2007) , which usually lack an EDS and lose Gbx2 expression by E10.5. This is consistent with the 9 idea that hindbrain, rather than epithelial Fgf3, induces the EDS. It is possible that the further 10 shortening of F3cHet/F10cKO CDs results from reduced FGF3-stimulated proliferation rather than 11 alterations in molecular patterning. This is supported by preliminary analyses of E18.5 ears that did 12 not reveal any exacerbation of changes to CD marker genes analyzed previously in the F10KO 13 mutant (data not shown, see Urness et al., 2015) . However, the timing of such proliferative effects in 14
F3cKO;F10cKO mutants must be later than E10.5, when differences in pHH3 labeling between 15 control and F3cKO/F10cKO otocysts were not significant. 16
We suggested previously that Fgf3 plays a role in otic ganglion development, as the F3KO 17 ganglion, like that of Fgfr2b null mutants (Pirvola et al., 2000) , is smaller than normal (Mansour et 18 al., 1993) . In contrast, F10KO early otic ganglia and later cochlear ganglia appear normal (Urness et 19 al., 2015) despite defects of vestibular innervation consequent to midgestation loss of vestibular 20 sensory epithelia (Pauley et al., 2003) . In contrast to zebrafish (Vemaraju et al., 2012) , our present 21 data from F3cKO;F10cKO mutants suggest that Fgf3 and Fgf10 are required together for 22 maintenance of Neurog1 and Neurod1 expression, and development of an otic ganglion, rather than 23 specification of otic neuroblasts. Our data do not address whether this requirement involves ligand 24 expression in the epithelium or ganglion or both. However, by restricting dnFGFR2b expression to 25 the placodal lineage by using Pax2-Cre in combination with the unrecombined Rosa26 lslrtTA allele, it 26 may be possible to avoid disrupting otic induction and determine whether FGFR2b ligands play any 27 role in mouse otic neuroblast specification. In addition, this paradigm of tissue restricted and timed 28 induction of dnFGFR2b could also be used to identify candidate genes responsible for neuroblast 29 maintenance. Determining the role of the transient burst of Fgf3 in delaminating neuroblasts will be 30 more challenging. 31
Temporally controlled inhibition of FGFR2b signaling during otocyst morphogenesis reveals 1 requirements at multiple stages 2
Observations of embryos expressing dnFGFR2b between E5.5 and E10.5 showed that this inhibition 3 strategy effectively phenocopies F3KO;F10KO mutants without causing abnormalities characteristic 4 of disrupting FGFs that signal through "c"-type receptors. Thus, dnFGFR2b has the expected 5 specificity and the only relevant FGFR2b ligands for otocyst morphogenesis are likely to be FGF3 6 and FGF10. Paintfilling of embryonic ears subjected to ubiquitous and chronic dnFGFR2b 7 expression starting on different days of development revealed that FGFR2b ligands are required 8 continuously for otic development at least through E13.5. Pulses of dnFGFR2b caused highly 9 specific and penetrant otic malformations, supporting the idea that unlike irreversible CRE-mediated 10 deletion of coding exons, the signaling inhibition effected by dnFGFR2b is reversible. 11
Together, the chronic and pulsed inhibition paradigms suggest a distinct progression of roles for 12
FGFR2b ligands: first in inducing the placode, then in stimulating EDS, vestibular pouch and CD 13 outgrowth, and finally in sculpting the SCCs, outgrowth of utricle and saccule, and specification of 14 CD nonsensory tissue. As otic induction is complete by ~E8.5, it was surprising that starting chronic 15 dnFGFR2b expression on E9.5 blocked ear development in 6/10 cases. Since dnFGFR2b embryos 16 from Seq3 inductions (E9.25-E10.25) always had otocysts, and these had significantly reduced 17 proliferation, we suggest that the loss of otic tissue in embryos induced chronically after E8.5 18 reflects degeneration of mitotically blocked cells rather than failure of otic induction. Some 19 phenotypes revealed the timing of roles for FGFR2b ligands. For example, the 6-24 hours starting at 20 E8.25 is particularly important for EDS formation, potentially reflecting FGF3 inhibition (Mansour 21 et al., 1993; Hatch et al., 2007) and the 6-hours starting at E9.25 is important for PSCC formation, 22 potentially reflecting FGF10 inhibition (Pauley et al., 2003; Urness et al., 2015) . Other vestibular 23 phenotypes are particularly interesting as they reveal three potential and previously unsuspected 24 functions for FGFR2b signaling. Chronic dnFGFR2b induction starting at E10.5, or 4-24 hour pulses 25 starting at E10.25 blocked fusion of vestibular pouches, suggesting requirements for FGFR2b 26 ligands in fusion plate formation and chronic induction starting between E11.5-E13.5 or 12-hour 27 pulses starting E9.75-E10.75 caused very thin semicircular canals, suggesting roles for FGFR2b 28 ligands in limiting resorption of fusion plates. Finally, several conditions reduced utricle and saccule 29 development. Thus, it will be interesting to explore regulatory relationships between FGFR2b 30 signaling and genes already known to regulate vestibular mophogenesis (Alsina and Whitfield, 31 2017), as well as to induce dnFGFR2b in particular temporal/spatial windows and pursue unbiased 32 identification of effector genes involved in the development of particular structures of interest. 33 1 FGFR2b ligands promote otic epithelial proliferation and prevent premature expression of 2 genes required for hearing 3
Our RNA-Seq datasets revealed significant downregulation of genes involved in the cell cycle and 4 DNA repair, and indeed, immunostaining of Seq3 samples showed that mitotic cell numbers were 5 significantly reduced in E10.25 dnFGFR2b-containing otocysts. This result differed from that 6 obtained with E10.5 F3cKO/F10cKO otocysts, which did not show a mitotic defect. Given that 7
hindbrain Fgf3 is unaffected in Pax2-Cre;F3cKO/F10cKO mutants, and is extinguished by E10.5, it 8 is likely that otocyst proliferation defects in these mutants would be detected at later stages of 9 morphogenesis. 10
The RNA-Seq datasets also revealed significantly upregulated genes. We found that in Seq1 and 11
Seq2, these genes are highly enriched for human hereditary hearing loss genes and mouse genes that 12 are expressed and/or function later in the inner ear. These include Pax2, which was expanded in 13 E10.5 F3cKO/F10cKO otocysts. This suggests that at early stages, FGFR2b signaling normally 14 represses many genes important for later development and function of the cochlea, or alternatively, 15 that the proliferative block imposed by dnFGFR2b expression promotes early differentiation of the 16 epithelium. The latter possibility however, does not apply to the earliest genes required for sensory 17 cell differentiation (Atoh1, Pou4f3 and Gfi1), which were detected at very low levels and were 18 unaffected in any of the RNA-Seq datasets. We suggest that the upregulated genesets are worth 19 mining for new candidates for hearing loss genes, of which many remain to be identified (Bowl and 20 Brown, 2018) . 21
Although we show that FGFR2b ligands are required to activate a Bmp (Bmp4) and repress a 22 BMP regulatory gene (Bmper), we found no evidence for FGFR2b ligand regulation of key 23 downstream components of the BMP or SHH pathways, suggesting that while FGFR2b ligands may 24 regulate individual components of these pathways, at least at the stages investigated, they are not 25 exclusively upstream of these key programs directing dorsal and ventral otic morphogenesis, 26 respectively. 27 28
Novel targets of FGFR2b signaling in early otocyst development 29
We validated by ISH seven novel genes downregulated and one gene upregulated by FGFR2b 30 ligands in the RNA-seq datasets. Some genes may be regulated directly by the intracellular signaling 31 pathway activated by FGFR2b, as one of our analysis points was only 12 hours after induction. As it 32
was not possible to study more than a few differentially expressed genes, it is difficult to speculate 33 about their combinatorial functions in inner ear development. Nevertheless, it is interesting to note 1 that the downregulated genes in our most robust dataset (Seq1) are enriched for transcription factor-2 coding genes (Excel S2), including those validated here, Six2, Prdm1 and Pou3f3. The first two have 3 otocyst expression patterns similar to Spred3, Crlf1 and Tspan15, whereas Pou3f3 expression 4 appears to overlap with Gchfr. This suggests that further mining of the existing differential 5 expression data and generation of additional targets by employing different windows of FGFR2b 6 inhibition, combined with promoter analysis and genomewide studies of otocyst chromatin 7 modification could suggest important new gene regulatory networks acting to shape the epithelium. 8
The only upregulated gene validated by ISH was Bmper, which encodes BMP-binding 9 endothelial regulator, an ortholog of Drosophila crossveinless-2 (cv-2) (Coffinier et al., 2002) . cv-2 10 modulates BMP signaling biphasically in the fly wing with the direction of action dependent upon 11 the concentration of Cv-2 and the concentration and types of local BMP ligands (Conley et al., 2000; 12 Serpe et al., 2008) . Similarly, in mouse, Bmper modulates the availability of BMPs, enhancing 13 signaling when ligands are low and limiting signaling when ligands are high (Dyer et al., 2014; 14 Kelley et al., 2009 ). Thus, Bmper null mutants have some phenotypes suggestive of a classic BMP 15 signaling antagonist (Moser et al., 2003) and others suggestive of a BMP signaling agonist (Ikeya et 16 al., 2006) . Multiple Bmps and their receptors are expressed in and required for otocyst 17 morphogenesis (Chang et al., 2008; Hwang et al., 2010; Ohyama et al., 2010) and misexpression of 18 BMP ventral to the otic placode blocks outgrowth of the chick cochlea (Ohta et al., 2016) . Thus, it 19 will be interesting to determine whether the otic phenotype of a Bmper null mutant reflects a loss or 20 gain of BMP signaling, and whether this differs in different regions of the developing otocyst. Our 21 results also showed that at early stages of otocyst morphogenesis, Fgf3 and Fgf10 are required for 22 expression of Bmp4, which is itself required for both vestibular and cochlear development (Chang et 23 al., 2008) . Determining whether FGFR2b ligand-dependent upregulation of Bmper functions in this 24 context to further antagonize BMP signaling, or alternatively, to mitigate the reduction in Bmp4 by 25 increasing signaling by other BMP ligands will require additional studies of otic Bmp expression and 26 manipulation of Bmper allele levels in combination with dnFGFR2b induction at different stages. 27
The identification of several FGFR2b target genes not implicated previously in ear development 28 or hearing loss syndromes provides a tantalizing glimpse into a new set of potential otocyst 29 morphogenetic factors. Given the novelty of these targets, it is tempting to speculate that previously 30 unappreciated regulatory pathways may be at play during otic morphogenesis, as has been postulated 31 for otic placode induction (Anwar et al., 2017) . Functional studies will be required to address the 32 roles of each of these new genes. 33 1
MATERIALS AND METHODS 2
Mouse models and genotyping 3
Mice were maintained and euthanized in accordance with protocols approved by the University of 4
Utah Institutional Animal Care and Use Committee. All Fgf mutant alleles were kept on a mixed 5 genetic background comprised of C57Bl/6 and various 129 substrains. CD-1 outbred mice (Charles 6 River Laboratory) were used to generate embryos for studies of normal expression patterns and for 7 generating embryos for induction of dnFGFR2b. Noon of the day a mating plug was observed was 8 considered E0.5. 9
Generation and PCR genotyping of the Fgf3 and Fgf10 null alleles (Fgf3 -, formally designated 10 Fgf3 tm1.1Sms = MGI:3767558 and Fgf10 − , formally designated Fgf10 tm1.1Sms = MGI:3526181) and 11
Fgf3 and Fgf10 and conditional alleles (Fgf3 c ; Fgf3 tm1.2Sms = MGI:4456396] and Fgf10 c ; Fgf10 tm1.2Sms 12 = MGI:4456398) were described previously (Hatch et al., 2007; Urness et al., 2010) . Tg(Pax2-Cre) 13 mice (Tg(Pax2-cre)1Akg = MGI:3046196) were obtained from Dr. Andrew Groves (Ohyama and 14 Groves, 2004) . Tg(Pax2-Cre) was detected by PCR using primers specific to the transgene (5' 15 GGGGATCCCGACTACAAGG 3'; 5' TAGTGAGTCGTATTAATTTCGATAAGC 3'). The 16 Sox1 Cre allele (Takashima et al., 2007) was transferred from Dr. Mario Capecchi with permission 17 from Dr. Shin-Ichi Nishikawa (RIKEN) and genotyped using generic Cre primers. Rosa26 lslLacZ 18 reporter mice (Gt(ROSA)26Sor tm1Sor = MGI:1861932) (Soriano, 1999) were maintained as 19
homogyzotes. 20
Single conditional mutants were generated by crossing Fgf3 c/c females to Fgf3 -/+ ;Tg(Pax2-Cre)/+ 21 males or Fgf10 c/c females to Fgf10 -/+ ;Tg(Pax2-Cre)/+ males. Combinations of Fgf3 and Fgf10 22 conditional mutants were obtained by crossing Fgf3 c/c ;Fgf10 c/c females to Fgf3 -/+ ;Fgf10 -/+ ;Tg(Pax2-23 Cre)/+ or Fgf3 -/+ ;Fgf10 -/+ ; Sox1 Cre/+ males. CRE activity was confirmed by mating males to 24 Rosa26 LacZR/LacZR females harvesting embryos at the indicated stages and staining with X-gal as 25 described (Yang and Mansour, 1999) . 26
The germline recombined Rosa26 rtTA allele (derived from Gt(ROSA)26Sor tm1(rtTA,EGFP)Nagy ; 27 MGI:3583817) (Belteki et al., 2005; Parsa et al., 2008) and Tg(tetO-dnFgfr2b) (Tg(tetO-28 Fgfr2b/Igh1.3Jaw; MGI 5582625) (Hokuto et al., 2003) alleles were transferred from the laboratory 29 of Dr. Saverio Bellusci with permission from Dr. Jeffery Whitsett (Cincinnati Children's Medical 30
Center). Genotyping primers to detect Tg(tetO-dnFgfr2b) were 5' 31 CAGGCCAACCAGTCTGCCTGGC 3' and 5' CGTCTGAGCTGTGTGCACCTCC 3'. ROSA26 rtTA 32 genotyping primers were ROSA5 (5' GAGTTCTCTGCTGCCTCCTG 3') and ROSA3 (5' 33 CGAGGCGGATCACAAGCAATA 3'), which generate a wild type band of 322 bp and ROSA5 and 1 RTTA3 (5' AAGACCGCGAAGAGTTTGTC 3'), which generate a 215 bp rtTA-specific product. 2 Double heterozygotes were obtained initially by crossing single heterozygotes. For most of the 3 studies described here, we crossed wild type CD-1 females to Rosa26 rtTA/rtTA ;Tg(tetO-dnFgfr2b)/+ 4 males, generating 50% each of control and experimental genotypes. 5 6 RNA in situ hybridization 7
Embryos were harvested and fixed in 4% PFA and stored in methanol at -20°C. RNA ISH to whole 8 mount embryos or paraffin-embedded sections were performed as described (Urness et al., 2008; 9 Urness et al., 2010) . Probes for Sox9, Fgf3, Fgf10, Bmp4, Etv5, Gbx2, Sox2, Foxg1, Pax2, NeuroD1, 10 Ngn1 and Crlf1 were generated by transcription of cDNA-containing plasmids. Template plasmids 11 and acknowledgements are shown in Table S1 . All other RNA probes were generated by 12 transcription of a PCR-amplified, gene-specific 3' UTR fragment containing a T7 promoter. The 13 primer sequences are shown in Table S2 . Whole embryos were photographed using a 14 stereomicroscope (Zeiss Discovery.V12) fitted with a digital camera (QImaging Micropublisher 15 5.0). Hybridized tissue sections were photographed under DIC illumination (Zeiss Axioskop) using a 16 digital camera (Zeiss Axiovision or Lumenera Infinity3). 17
Immunostaining of frozen tissue sections for quantification of mitotic cells in the otocyst 19
Embryos were fixed in 4% paraformaldehyde solution and cryosectioned in the transverse plane for 20 immunostaining as described (Urness et al., 2015) . Rabbit anti-phosphohistone H3 (Millipore 06-21 570) was applied at a dilution of 1:400 and mouse monoclonal anti-E-cadherin (BD Biosciences 22 610181) was diluted 1:60. Secondary antibodies were from Invitrogen and diluted 1:400 into 23 PBST/5% normal serum (Alexa Fluor ® 488 goat anti-rabbit (A11034) and Alexa Fluor ® 594 goat 24 anti-mouse (A11032)). DAPI was included in the mounting medium (Vectashield, Vector Labs). 25 
Paint filling of embryonic inner ears 4
Filling of embryonic inner ears with latex paint and photography was as described previously 5 (Urness et al., 2015) . 6 7
Induction of dnFGFR2b expression 8
Initial inductions of dnFGFR2b designed to phenocopy Fgf3/Fgf10 double mutants were achieved 9 by feeding pregnant females DOX chow (200 mg/kg, Custom Animal Diets, LLC) ad libitum for the 10 indicated time periods (E5.5-E10.5, E5.5-E11.5 or E6.5-E11.5). All subsequent inductions to 11 generate samples for paintfilling, RNA-seq, ISH or immunostaining were initiated by a single 12 intraperitoneal injection of the pregnant dam with 0.1 ml/10 g body weight of 0.15 mg/ml (1.5mg/kg 13 body weight) doxycycline hyclate (Sigma-Aldrich) prepared in PBS followed by provision of DOX 14 chow ad libitum for the indicated time periods. We avoided using female Rosa26 rtTA parents, as these 15 seemed to require larger and variable amounts of DOX to see phenotypes than when rtTA was 16 contributed by the male parent, presumably because the widespread, ubiquitous expression of rtTA 17 in females served to sequester DOX. We did not measure the time needed to reactivate signaling 18 after DOX withdrawal, but based on studies of the limb (Danopoulos et al., 2013) , we expect that 19 signaling resumes after 12-24 hours. 20 21
Otic vesicle preparation and RNA isolation 22
Embyos from timed matings of CD-1 females and Rosa26 rtTA/rtTA ;Tg(tetO-(s)dnFgfr2b)/+ males, 23
with DOX exposures as specified, were dissected and the yolk sacs saved for genotyping. The otic 24 vesicles, including surrounding mesenchyme, were crudely dissected from the head. Isolation of the 25 vesicles free of mesenchyme was accomplished similarly to methods previously described (Urness et 26 al., 2010) with the following modifications. Otocysts with adherent mesenchyme were incubated in 27 50 µl ice-cold PT solution (25 mg/ml pancreatin (Sigma), 5 mg/ml trypsin (Sigma), and 5 mg/ml 28 polyvinylpyrrolidone MW360 (Sigma) in Tyrode's solution) for ~7 min. (E10.25), or ~8 min. 29 (E11.25) to promote separation of the mesenchyme. Otocysts were aspirated to Hepes-DMEM-10% 30 FBS, where the digested mesenchyme could be gently teased from the underlying epithelium using 31 fine forceps or tungsten needles, and by "rolling" the vesicle over the bottom of the dish to detach 32 the mesenchyme as it adhered to the plastic. The two otocysts from each embryo were aspirated into 33 100 µl RNALater (Ambion) and stored at -20°C prior to genotyping. For each of four pregnant 1 females per DOX induction regime, all otocysts of the same genotype were combined into paired 2 control (Rosa26 rtTA/+ ) and experimental (Rosa26 rtTA/+ ;Tg-(tetO-(s)dnFgfr2b)/+) pools (n = 6-12 3 otocysts/pool). 4
Total RNA from each control and experimental otocyst pool was prepared using a Micro RNAeasy 5 kit (Qiagen #74004) and analyzed for quantity and quality on a BioAnalyzer RNA TapeStation. All (coverage per million mapped reads) were generated using USeq Sam2USeq and USeq2UCSCExe. 18
Read counts for each gene were generated using USeq DefinedRegionDifferentialSeq (Nix et al., 19 2008) and differential expression analysis was performed using DESeq2 (Love et al., 2014) . 20
To inspect Fgfr splicing we merged each set of control and dnFgfr2b alignments to 21 separate .bam files, uploaded them to IGV 2.4.10 (Robinson et al., 2011; Thorvaldsdottir et al., 22 2013 ) and generated Sashimi plots. To identify significantly regulated pathways (P<0.05, Fisher's 23
Exact Test), all differentially expressed genes were loaded into Ingenuity Pathway Analysis 24 (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). For 25 GSEA analysis, two custom gene sets based on human hearing loss genes from Nishio et al. (2015) 26 and mouse inner ear genes from Ohlemiller et al. (2016) were loaded into the Broad Institute GSEA 27 website (Subramanian et al., 2005) Funded by grants from the National Institute of Health to SLM (R01 DC011819 and R01 9 DC002043). EG-M was supported by an SDB CHOOSE Development! fellowship. 10
DATA AVAILABILITY 11
The three RNA-seq datasets are deposited in GEO under accession #GSE116404. 12 row. Scale and orientation for all panels indicated in A. 32 Supplemental Table Legends  1   Table S1 : cDNA clones used to prepare digoxigenin-labeled cRNA antisense transcripts for in 2 situ hybridization 3
FIGURE LEGENDS 1
Purified plasmid DNA was digested with the indicated restriction enzyme and then transcribed with 4 the indicated RNA polymerase to produce antisense probes for ISH. 5 6 Table S2 : Primers used to generate DNA fragments for cRNA probe generation. 7
Forward (F) and reverse (R) primers used to PCR-amplify 3'UTR regions of each indicated gene 8 from mouse genomic DNA, except Crlf1, which was amplified from a cDNA clone. All reverse 9 primers include the T7 promoter sequence (GGATCCTAATACGACTCACTATAGGGAG) at the 10 5' end. The antisense-RNA strand was produced by transcription of the PCR product using T7 RNA 11 polymerase. Crlf1 cDNA 3 from DNASU Arizona State University Clone # MmCD00295268 12 (NCBI NM_018827.2, Image: 100063851). 13 Table S1 cDNA clones used to prepare digoxigenin-labeled cRNA antisense transcripts for in situ Purified plasmid DNA was digested with the indicated restriction enzyme and then transcribed with the indicated RNA polymerase to produce antisense probes for ISH. RNA-Seq3 (DOX exposure from E9.25-E10.25) datasets. Down-regulated (green) and up-regulated (red) genes were identified using a paired statistical model (see Methods). The statistical significance of the differential expression is shown on the y-axis and the fold change is shown on the x-axis.
Names for genes highlighted in yellow include all those with a fold-change > 1.5, plus known FGF target genes and genes that we pursued for expression validation. . The statistical significance of the differential expression is shown on the y-axis and the fold change is shown on the x-axis. Names for genes highlighted in yellow include all those with a fold-change > 1.5, plus known FGF target genes and genes that we pursued for expression validation. 
